NEWS

MARKET-TEST-DUMMY : That sucks

Salmon Klein : what? CEO bought one mullion or more in shares just few months ago isn't? and now coming otc jesus

Salmon Klein : btw, you have experience on medical stuff, have you seen verastem? news are very promising but dropped like crazy, no sure if offering or what, I meed to find out and I may jump in once it stabilizes

Jaguar8 OP Salmon Klein : He will profit either way.

Salmon Klein Jaguar8 OP : I am sire about that hehehe

Jaguar8 OP Salmon Klein : VSTM study on pancreatic Cancer is good . However the attrition rate owing to adverse events greatly affected the stock movement. Take note that the published result is just interim. This is one of the deadliest cancer there is and any combination of medication to reduce lesions to prolong life is significant. Let us monitor how they progress with the trial.

Salmon Klein Jaguar8 OP : thanks. I didn't get what you mean by attrition rate? Do you mean people are badly affected by the study? with secondary effects? anyways is worth keeping an eye on this one, if company is decent worth to invest later on

Jaguar8 OP Salmon Klein : Attrition rate pertains to number of people dropped out of study

Salmon Klein Jaguar8 OP : ok ok a bit technical for a non native speaker hehehe Thanks for the clarification...I guess that's normal because the drug must be agreesive too

Jaguar8 OP Salmon Klein : Yes